acute ischemic stroke (AIS)
Conditions
Interventions
Experimental group:Treatment of Edaravone Dexborneol injection
Control group:Standard treatment of AIS
Sponsors
Department of Neurology, Ruian People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Diagnosed as ischemic stroke; 2. Aged 18-80 years; 3. Receive intravenous thrombolytic therapy with RT-PA within 4.5 hours of stroke onset; 4. Informed consent signed by patients or their family members.
Exclusion criteria
Exclusion criteria: 1. Intracranial hemorrhagic diseases observed by head CT: hemorrhagic stroke, epidural hematoma, intracranial hematoma, ventricular hemorrhage, subarachnoid hemorrhage, etc.; 2. Severe disturbance of consciousness: NIHSS scored more than 1 in item 1a of consciousness level; 3. Patients with severe mental disorders and dementia; 4. mRS score was >1 before the onset of the disease; 5. Transient ischemic attack (TIA); 6. After blood pressure control, systolic blood pressure was still >=220mmHg or diastolic blood pressure >=120mmHg; 7. Free radical scavenger such as Edaravone and reduced glutathione have been applied since the onset of the disease; 8. ALT or AST>2.0xULN or previously known liver diseases, such as acute hepatitis, chronic active hepatitis, cirrhosis, previously known kidney disease, renal insufficiency, serum creatinine >1.5xULN or creatinine clearance <50mL/min; 9. Concurrent malignant tumor or undergoing antitumor therapy; 10. Severe systemic disease with an estimated survival of less than 90 days; 11. Allergic to Edaravone, (+) -2-camphenol, or excipients; 12. Patients during pregnancy, lactation and planning pregnancy; 13. Other conditions deemed unsuitable for participation in this clinical study by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Modified Rankin scale score at 90 days; | — |
Countries
China
Contacts
Public ContactHuang Xuerong
Outcome results
None listed